Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders
Multicenter Study of Long-Term Outcomes and Quality of Life in PHACE Syndrome after Age 10
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
Early diagnosis of ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis syndrome: A case report
Cotton, C. H., Chen, S. X., Hussain, S. H., Lara-Corrales, I ., & Zaenglein, A. L. (2023). Hidradenitis Suppurativa in Pediatric Patients . Pediatrics, 151(5), e2022061049.
— 2023cited by 0position: selected
Liy-Wong, C., Tarango, C., Pope, E., Coates, T., Bruckner, A. L., Feinstein, J. A., Schwieger-Briel, A., Hubbard, L. D., Jane, C., Torres-Pradilla, M., Zmazek, M., & Lara-Corrales, I. (2023). Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa . Orphanet journal of r
— 2023cited by 0position: selected
Fern á ndez Faith, E., Shah, S. D., Braun, M., Pope, E., Lara-Corrales, I., Witman, P. M., Harfmann, K., Bradley, F., Keesari, R., Jackson, K., Hallagan, A., & Frieden, I. J. (2023). Incidence and Clinical Factors Associated with Ulceration in Infantile Hemangiomas . Journal of the American Academy
— 2023cited by 0position: selected
Han, J., Dykman, M., Lunos, S., Nguyen, A., Hook, K. P., Lara-Corrales, I. , Price, H. N., Diaz, L., Levy, M., & Boull, C. (2023). Transition of care in patients with epidermolysis bullosa: A survey study . Pediatric dermatology, 40(2), 258–260.
— 2023cited by 0position: selected
2022–Present: CoPI. Management of Reactive Infectious Mucocutaneous Eruption (RIME) in Children. Lara-Corrales I, Ramien Michele. 2022 PeDRA Consensus Grant ($25,000 USD)
— 2022cited by 0position: selected
Hidradenitis Suppurativa in the Pediatric Population
Blistering severe cutaneous adverse reactions in children: proposal for paediatric‐focused clinical criteria
Dermatology COVID-19 Registries
Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database
Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus‐based guidance for clinical decision‐making during the COVID‐19 pandemic
2019–2022: The Efficacy and Safety of AVC-516942 (3% Cannabidiol) Cream in Patients with Epidermolysis Bullosa: A Phase II/III trial. Avicanna Canada.
— 2019cited by 0position: selected
Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis
Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey
“Eczema Coxsackium” and Unusual Cutaneous Findings in an Enterovirus Outbreak
Gastrointestinal Bleeding in Infantile Hemangioma: A Complication of Segmental, Rather than Multifocal, Infantile Hemangiomas